Sexual dysfunction among male patients on antidepressant theraphy

2011 ◽  
Vol 26 (S2) ◽  
pp. 1554-1554
Author(s):  
V. Sibinovic ◽  
S. Tosic-Golubovic ◽  
G. Selimovic

IntroductionSexual dysfunction is common among individuals with major depressive disorder but not optimally treated often.ObjectivesThe aim of this study was to determine differece in sexual dysfunction among male patients on antidepressant theraphy.MethodsStadu group consisted of 69 male outpatients who met DSM IV criteria for Major depressive disorder; aged 21–65 (mean 46.3 years). Studu excluded patients: with a previous history of sexual dysfunction, somatic diseases, other psychiatric co morbid condition. They did not used medication able to cause sexual dysfunction unless antidepressants or medications to improve erectile dysfunction. The ASEX and HDRS scales were applied at a single interview.ResultsThe prevalence of sexual dysfunction observed was 66% patients, 57, 7% in group under 50 and 74, 3% in group being 50 years old or older.Sexual dysfunction, revealed by a high score on the ASEX scale (mean overall score of 26.9) was in group of patient over 50 years old. (p < 0, 01). There are no statistical, significant differences in the points obtained on the HDRS scores in both groups. (p < 0.01). Sexual dysfunction were reported more frequently in patients taking TCA (p < 0.005) or SSRIs (p < 0.001) compared to patients treated with mirtazapine.The use of TCA is associated with loss of libido and erectile dysfunction, SSRIs with delayed ejaculation as well as impairment of libido and arousal.ConclusionsFrequency of sexual dysfunction is higher in patients over 50 years. The less impact on sexual function have mirtazapine.

2020 ◽  
Vol 2 (3-4) ◽  
pp. 281-283
Author(s):  
Roshan Sutar ◽  
Faisal Siddiqui ◽  
Abin Rajan

Commonly prescribed antidepressants are associated with sexual adverse effects predominantly reported as erectile dysfunction by men. The clinical dilemma of choosing the right antidepressant while not compromising the sexual functioning is an area of recent research. Few antidepressants, namely dapoxetine, bupropion, trazodone, and mirtazapine, have been reported to have minimal sexual adverse effects. Vortioxetine is a relatively newer antidepressant with clinical profile having minimal sexual and cognitive adverse effects. However, improvement in sexual dysfunction after treatment with vortioxetine has not been reported so far. We highlight the unique benefit of vortioxetine in improving sexual dysfunction in a case of major depressive disorder.


2021 ◽  
Vol 18 (12) ◽  
pp. 2005-2011
Author(s):  
Sirpi Nackeeran ◽  
Amoghavarsha Havanur ◽  
Jesse Ory ◽  
Stanley Althof ◽  
Ranjith Ramasamy

2019 ◽  
Vol 57 ◽  
pp. 46-51 ◽  
Author(s):  
Suhaer Zeki Al-Fadhel ◽  
Hussein Kadhem Al-Hakeim ◽  
Arafat Hussein Al-Dujaili ◽  
Michael Maes

AbstractObjective:Activation of the immune-inflammatory response system (IRS) and the compensatory immune-regulatory system (CIRS) and aberrations in endogenous opioids play a role in the pathophysiology of major depressive disorder (MDD). There are no studies which examined the associations between both systems in MDD. The aim of the present study was to examine the relation between β-Endorphin (β-EP), Endomorphin-2, and their mu-opioid receptor (MOR) as well as interleukin (IL)-6 and IL-10, an anti-inflammatory cytokine, in MDD patients.Method:The study included 60 depressed drug-free male patients and 30 matched controls. Serum β-EP, Endomorphin-2, MOR, IL-6 and IL-10 levels were measured using ELISA techniques.Results:The results revealed a significant increase in serum β-EP, MOR, IL-6 and IL-10 in MDD patients versus healthy controls. MOR levels were strongly associated with IL-10 levels. There were no significant correlations between endogenous opioids and IL-6 and IL-10.Conclusion:The results show that MOR levels may function as a possible component of the CIRS whilst there is no evidence that β-EP and EM-2 may modify the IRS. The significant correlation between MOR levels and IL-10 may be explained through central activation of the HPA-axis and increased B-cell numbers expressing MOR as a response to cytokine over-secretion in MDD.


Sign in / Sign up

Export Citation Format

Share Document